Carolyn L. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolyn L. Wang has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Ryan B. O'MAlley
Department of Radiology, University of Washington School of Medicine, Seattle, USA
6 shared publications Daniel S. Hippe
Department of Radiology, University of Washington, Box 357115, 1959 NE Pacific St, Seattle, WA 98195-7115
5 shared publicationsWilliam H. Bush
Department of Radiology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Ave E, G2-600, Seattle, WA 98109-1023
5 shared publicationsErik V. Soloff
Department of Radiology, University of Washington, Seattle, USA
4 shared publications- Matthew S. Davenport
Departments of Radiology and Urology, Michigan Medicine, Ann Arbor, Mich
4 shared publications Angelisa M. Paladin
University of Washington
3 shared publications
Latest Publications
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1029-1047
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement From the American College of Radiology and the American Academy of Allergy, Asthma, & Immunology
- 6 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (5) , 1029-1047
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement From the American College of Radiology and the American Academy of Allergy, Asthma, & Immunology
- 1 May 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (2) , e240100
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology
Key outcomes from a multidisciplinary task force on hypersensitivity reactions to iodinated contrast media include recommendations to document reactions thoroughly in the electronic health record, including symptoms and the specific inciting agent, and a discussion of varying strategies for avoidance of repeat acute hypersensitivity reactions to iodinated contrast media according to the severity of the index reaction; importantly, no corticosteroid premedication is generally recommended for patients with a prior mild acute hypersensitivity reaction.
- 1 May 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (2) , e240100
Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology
Key outcomes from a multidisciplinary task force on hypersensitivity reactions to iodinated contrast media include recommendations to document reactions thoroughly in the electronic health record, including symptoms and the specific inciting agent, and a discussion of varying strategies for avoidance of repeat acute hypersensitivity reactions to iodinated contrast media according to the severity of the index reaction; importantly, no corticosteroid premedication is generally recommended for patients with a prior mild acute hypersensitivity reaction.
- 28 January 2025
- Published by Springer Nature in European Radiology
- Vol. 35 (8) , 4417-4428
Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients
Objective To investigate the predictive value of tumor iodine concentration obtained with dual-energy CT (DECT) for treatment response in patients treated with immune checkpoint inhibitors (ICI). Materials and methods Retrospective single-center study of consecutive metastatic melanoma and renal cell carcinoma (RCC) patients undergoing first-line ICI treatment. The iodine concentration measurement time points include prior to initiation of therapy (baseline [BL]), after initiation (follow-up [FU1]), and either time point nearest to 12 months or at time of progression (final follow-up [FFU]). Target lesion DECT-based whole-volume tumor normalized iodine concentration average (NICave) and size measurements were obtained. Reference standard was individual lesion FFU status categorized as responders or nonresponders per RECIST 1.1. Logistic regression model assessed NICave change and FU1 lesion response as predictors of FFU lesion outcome. Model’s performance was summarized with AUC. Intraclass correlation coefficient (ICC) summarized inter-rater agreement of NICave. Results Forty-six patients were included (mean age 61 ± 11 years, 12 women; 16 melanoma). Sixty-four of 175 target lesions were confirmed nonresponders at FFU. In a multivariable model, lesion status at FU1 (odds ratio [OR]: 27.4, p < 0.001) and changes in NICave from BL to FU1 (OR: 2.42 per 1-SD increase, p = 0.019) were significant predictors of lesion status at FFU. The model’s AUC was 0.86 (95% CI: 0.76–0.93). Inter-rater reliability of NICave was 0.98 (95% CI: 0.97–0.99). Conclusions Changes in iodine concentration from baseline to first follow-up improve identification of delayed responding metastatic melanoma and RCC lesions treated with immune checkpoint inhibitor, initially classified as nonresponders by size change. Key Points Question How can pseudoprogression/delayed treatment response in metastatic renal cell carcinoma (RCC) and melanoma patients on first-line immune checkpoint inhibitors be accurately identified? Findings Combining iodine concentration change from Dual-energy CT (baseline to first follow-up) with RECIST-based lesion size change improved prediction of final lesion outcome. Clinical relevance DECT-based whole-volume tumor iodine concentration for target lesions is useful as a predictive imaging biomarker for distinguishing delayed response from true progression in patients with metastatic RCC and melanoma treated with first-line immune checkpoint inhibitors. Graphical Abstract
- 28 January 2025
- Published by Springer Nature in European Radiology
- Vol. 35 (8) , 4417-4428
Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients
Objective To investigate the predictive value of tumor iodine concentration obtained with dual-energy CT (DECT) for treatment response in patients treated with immune checkpoint inhibitors (ICI). Materials and methods Retrospective single-center study of consecutive metastatic melanoma and renal cell carcinoma (RCC) patients undergoing first-line ICI treatment. The iodine concentration measurement time points include prior to initiation of therapy (baseline [BL]), after initiation (follow-up [FU1]), and either time point nearest to 12 months or at time of progression (final follow-up [FFU]). Target lesion DECT-based whole-volume tumor normalized iodine concentration average (NICave) and size measurements were obtained. Reference standard was individual lesion FFU status categorized as responders or nonresponders per RECIST 1.1. Logistic regression model assessed NICave change and FU1 lesion response as predictors of FFU lesion outcome. Model’s performance was summarized with AUC. Intraclass correlation coefficient (ICC) summarized inter-rater agreement of NICave. Results Forty-six patients were included (mean age 61 ± 11 years, 12 women; 16 melanoma). Sixty-four of 175 target lesions were confirmed nonresponders at FFU. In a multivariable model, lesion status at FU1 (odds ratio [OR]: 27.4, p < 0.001) and changes in NICave from BL to FU1 (OR: 2.42 per 1-SD increase, p = 0.019) were significant predictors of lesion status at FFU. The model’s AUC was 0.86 (95% CI: 0.76–0.93). Inter-rater reliability of NICave was 0.98 (95% CI: 0.97–0.99). Conclusions Changes in iodine concentration from baseline to first follow-up improve identification of delayed responding metastatic melanoma and RCC lesions treated with immune checkpoint inhibitor, initially classified as nonresponders by size change. Key Points Question How can pseudoprogression/delayed treatment response in metastatic renal cell carcinoma (RCC) and melanoma patients on first-line immune checkpoint inhibitors be accurately identified? Findings Combining iodine concentration change from Dual-energy CT (baseline to first follow-up) with RECIST-based lesion size change improved prediction of final lesion outcome. Clinical relevance DECT-based whole-volume tumor iodine concentration for target lesions is useful as a predictive imaging biomarker for distinguishing delayed response from true progression in patients with metastatic RCC and melanoma treated with first-line immune checkpoint inhibitors. Graphical Abstract
- 10 June 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (10) , 624-631
Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies
- 10 June 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (10) , 624-631
Pooled rate of pseudoprogression, patterns of response, and tumor burden analysis in patients undergoing immunotherapy oncologic trials for different malignancies
- 28 November 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (3) , 823-841
Imaging of abdominopelvic oncologic emergencies
With advancements in cancer treatment, the survival rates for many malignancies have increased. However, both the primary tumors and the treatments themselves can give rise to various complications. Acute symptoms in oncology patients require prompt attention. Abdominopelvic oncologic emergencies can be classified into four distinct categories: vascular, bowel, hepatopancreatobiliary, and bone-related complications. Radiologists need to be familiar with these complications to ensure timely diagnosis, which ultimately enhances patient outcomes. Graphical abstract
- 28 November 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (3) , 823-841
Imaging of abdominopelvic oncologic emergencies
With advancements in cancer treatment, the survival rates for many malignancies have increased. However, both the primary tumors and the treatments themselves can give rise to various complications. Acute symptoms in oncology patients require prompt attention. Abdominopelvic oncologic emergencies can be classified into four distinct categories: vascular, bowel, hepatopancreatobiliary, and bone-related complications. Radiologists need to be familiar with these complications to ensure timely diagnosis, which ultimately enhances patient outcomes. Graphical abstract
- 19 May 2022
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 19 (7) , 834-835
Statement from the ACR Committee on Drugs and Contrast Media on the Intravenous Iodinated Contrast Media Shortage
- 19 May 2022
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 19 (7) , 834-835
Statement from the ACR Committee on Drugs and Contrast Media on the Intravenous Iodinated Contrast Media Shortage
- 1 March 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (3) , 611-619
Virtual Unenhanced Dual-Energy CT Images Obtained with a Multimaterial Decomposition Algorithm: Diagnostic Value for Renal Mass and Urinary Stone Evaluation
Virtual unenhanced images from a dual-energy CT multimaterial decomposition algorithm yield renal mass attenuation comparable to true unenhanced images for both enhancing renal masses and nonenhanc... Background Virtual unenhanced (VUE) images obtained by using a dual-energy CT (DECT) multimaterial decomposition algorithm hold promise for diagnostic use in the abdomen in lieu of true unenhanced ...
- 1 March 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (3) , 611-619
Virtual Unenhanced Dual-Energy CT Images Obtained with a Multimaterial Decomposition Algorithm: Diagnostic Value for Renal Mass and Urinary Stone Evaluation
Virtual unenhanced images from a dual-energy CT multimaterial decomposition algorithm yield renal mass attenuation comparable to true unenhanced images for both enhancing renal masses and nonenhanc... Background Virtual unenhanced (VUE) images obtained by using a dual-energy CT (DECT) multimaterial decomposition algorithm hold promise for diagnostic use in the abdomen in lieu of true unenhanced ...
- Top Cited PapersOpen Access
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (1) , 28-35
Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] 2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 298 (1) , 28-35
Top Cited PapersOpen AccessUse of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] 2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
- 1 November 2020
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 44 (6) , 812-820
Diagnostic Yield of Computed Tomography for the Identification of Coronavirus Disease 2019 Using Repeated Reverse Transcriptase Polymerase Chain Reaction Testing or Confirmed True-Negative State as Reference Standard: Systematic Review and Meta-Analysis
Objective: The aim of this study was to perform a meta-analysis assessing the diagnostic yield of computed tomography (CT) for the identification of coronavirus disease 2019 (COVID-19) using repeated reverse transcriptase polymerase chain reaction testing or confirmed true-negative state as reference standard. Methods: In May 2020, we interrogated the MEDLINE, Embase, and CENTRAL databases. Pooled sensitivity, specificity, and diagnostic odds ratios of CT for COVID-19 identification were computed. Cumulative positive predictive value (PPV) and negative predictive value, stratified by disease prevalence, were calculated. Results: Ten articles were included (1332 patients). Pooled sensitivity, specificity, and summary diagnostic odds ratio of CT were 82% [95% confidence interval (CI), 79%–84%], 68% (95% CI, 65%–71%), and 18 (95% CI, 9.8–32.8). The PPV and negative predictive value were 54% (95% CI, 30%–77%) and 94% (95% CI, 88%–99%) at a COVID-19 prevalence lower than 40%, and 80% (95% CI, 62%–91%) and 77% (95% CI, 68%–85%) at a prevalence higher than 40%. Conclusion: CT yields higher specificity and PPV, albeit lower sensitivity, than previously reported for the identification of COVID-19.
- 1 November 2020
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 44 (6) , 812-820
Diagnostic Yield of Computed Tomography for the Identification of Coronavirus Disease 2019 Using Repeated Reverse Transcriptase Polymerase Chain Reaction Testing or Confirmed True-Negative State as Reference Standard: Systematic Review and Meta-Analysis
Objective: The aim of this study was to perform a meta-analysis assessing the diagnostic yield of computed tomography (CT) for the identification of coronavirus disease 2019 (COVID-19) using repeated reverse transcriptase polymerase chain reaction testing or confirmed true-negative state as reference standard. Methods: In May 2020, we interrogated the MEDLINE, Embase, and CENTRAL databases. Pooled sensitivity, specificity, and diagnostic odds ratios of CT for COVID-19 identification were computed. Cumulative positive predictive value (PPV) and negative predictive value, stratified by disease prevalence, were calculated. Results: Ten articles were included (1332 patients). Pooled sensitivity, specificity, and summary diagnostic odds ratio of CT were 82% [95% confidence interval (CI), 79%–84%], 68% (95% CI, 65%–71%), and 18 (95% CI, 9.8–32.8). The PPV and negative predictive value were 54% (95% CI, 30%–77%) and 94% (95% CI, 88%–99%) at a COVID-19 prevalence lower than 40%, and 80% (95% CI, 62%–91%) and 77% (95% CI, 68%–85%) at a prevalence higher than 40%. Conclusion: CT yields higher specificity and PPV, albeit lower sensitivity, than previously reported for the identification of COVID-19.
- 1 October 2020
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 215 (4) , 896-902
Comparison of Histogram-Based Gaussian Analysis With and Without Noise Correction for the Characterization of Indeterminate Adrenal Nodules
OBJECTIVE. The purpose of this study is to determine whether gaussian-based histogram analysis without and with noise correction can characterize indeterminate adrenal nodules (those with attenuati...
- 1 October 2020
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 215 (4) , 896-902
Comparison of Histogram-Based Gaussian Analysis With and Without Noise Correction for the Characterization of Indeterminate Adrenal Nodules
OBJECTIVE. The purpose of this study is to determine whether gaussian-based histogram analysis without and with noise correction can characterize indeterminate adrenal nodules (those with attenuati...